Physician profile
Charles Friedlander
NPI 1811911670
$1,486.11
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $155 · 2021: $175 · 2022: $90.28.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $486.30 | 2019-2020 | |
| Pfizer INC. | $310.03 | 2019-2022 | |
| Qol Medical, LLC | $164.99 | 2019-2020 | |
| Abbvie INC. | $159.12 | 2019-2020 | |
| Janssen Biotech, INC. | $83.28 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.84 | 2019 | |
| Merck Sharp & Dohme LLC | $59.80 | 2019-2020 | |
| Allergan, INC. | $58.59 | 2019-2020 | |
| Eisai INC. | $24.31 | 2019 | |
| Ferring Pharmaceuticals INC. | $22.72 | 2019 | |
| Napo Pharmaceuticals INC | $21.65 | 2019 | |
| Amarin Pharma, INC. | $14.48 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Friedlander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.